COMMUNIQUÉS West-GlobeNewswire

Ipsen - Octobre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/11/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
07/11/2025
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines NANTES, France, November 7, 2025 – 6:00pm CET - OSE [...]
Présentation poster sur OSE-Cytomask®, une technologie innovante de « Cis-Démasquage » des cytokines visant à augmenter l’indice thérapeutique des immunocytokines
07/11/2025
Présentation poster sur OSE-Cytomask®, une technologie innovante de « Cis-Démasquage » des cytokines visant à augmenter l’indice thérapeutique des immunocytokines Nantes, le 7 novembre 2025, 18 heures - OSE [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
07/11/2025
COPENHAGEN, Denmark, November 7, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5,13% [...]
Monthly information on share capital and company voting rights
07/11/2025
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/11/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 07 nov. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Chemed Corporation Declares Quarterly Dividend of 60 Cents
07/11/2025
CINCINNATI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 60-cents per share on the Company’s capital stock, [...]
ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)
07/11/2025
– Single subcutaneous dose of ADX-038 achieved n ear-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the efficacy and safety [...]
Trading by management and close relations of management
07/11/2025
Please read the full announcement in PDF Attachment 2025_48_Trading_By_Management
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
07/11/2025
-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate [...]
Virbac : Declaration of the number of shares and voting rights 10/2025
07/11/2025
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 10/2025
07/11/2025
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Easy Environmental Solutions Begins Trading Under New Ticker Symbol “EZES”
07/11/2025
Company prepares for first Easy FEN™ system deployment in Africa as part of global expansion strategy MANKATO, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Easy Environmental Solutions, Inc. (OTC: EZES) (“Easy Environmental [...]
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
07/11/2025
40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful [...]
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
07/11/2025
Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic [...]
Tizona Therapeutics Presents Clinical Translational Evidence of Dual Innate and Adaptive Immune Activation with TTX-080, a First-in-Class HLA-G Antagonist, in Patients with Advanced Solid Tumors at SITC 2025
07/11/2025
Enrolling patients in ongoing randomized Phase 1b trial in MSS metastatic colorectal cancer, evaluating TTX-080 in combination with cetuximab + FOLFIRI SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- [...]
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
07/11/2025
Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted [...]
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
07/11/2025
Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1 Evidence of immune activation and tumor-immune remodeling [...]
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
07/11/2025
EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases [...]

Pages